Comprehensive laboratory testing for adoptive cell therapies: Supporting preclinical and clinical testing to advance your precision medicine initiative

Adoptive cell therapies (ACTs) can deliver transformative approaches to patient care. Whether you are working with tumor-infiltrating lymphocytes, gene-modified T-cells expressing novel T-cell receptors, chimeric antigen receptor T-cells (CAR T) or CAR natural killer cells, we can support your laboratory assessments across the development continuum. To help you handle the unique challenges and complexities you face with developing these precision medicines, we provide a wide range of preclinical, CMC release and clinical testing across our in-house and specialty laboratories. Working together, we'll collaborate on a custom approach that will match the expert support you need to propel your high-impact ACT projects forward.